Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catalyst Bio (CBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 296,112
  • Shares Outstanding, K 11,940
  • Annual Sales, $ 1,020 K
  • Annual Income, $ -21,560 K
  • 36-Month Beta 2.48
  • Price/Sales 317.02
  • Price/Cash Flow N/A
  • Price/Book 2.26

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.30 +2.08%
on 05/22/18
29.95 -17.20%
on 05/17/18
-2.52 (-9.22%)
since 04/20/18
3-Month
22.61 +9.69%
on 04/03/18
31.55 -21.39%
on 03/06/18
-1.75 (-6.59%)
since 02/22/18
52-Week
3.11 +697.43%
on 08/24/17
37.00 -32.97%
on 02/12/18
+20.90 (+535.90%)
since 05/22/17

Most Recent Stories

More News
New Research Coverage Highlights BlackRock Capital Investment, Tootsie Roll Industries, Catalyst Biosciences, Macerich, Quotient Technology, and PennyMac Mortgage Investment Trust -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of BlackRock Capital Investment...

BKCC : 6.10 (-0.33%)
PMT : 18.67 (-0.16%)
CBIO : 24.80 (-8.28%)
TR : 28.15 (unch)
MAC : 55.04 (-0.18%)
QUOT : 13.45 (-3.93%)
Catalyst Biosciences Announces Oral Presentation at the World Federation of Hemophilia 2018 World Congress

Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced an oral presentation of clinical...

CBIO : 24.80 (-8.28%)
Catalyst Biosciences to Host Key Opinion Leader Meeting on Novel Treatments for Hemophilia B and Hemophilia with Inhibitors

Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it will host a Key Opinion Leader (KOL) breakfast on the topic of novel treatments for hemophilia B and hemophilia with inhibitors at 8:00...

CBIO : 24.80 (-8.28%)
Catalyst Biosciences Reports First Quarter Operating & Financial Results and Provides Corporate Update

Announced Korean Ministry of Food and Drug Safety approval to add sixth cohort to the Phase 1/2 trial of CB 2679d/ISU304 in individuals with hemophilia B

CBIO : 24.80 (-8.28%)
Catalyst Biosciences Announces Presentation at the 2018 Association for Research in Vision and Ophthalmology Annual Meeting

Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced a poster presentation with...

CBIO : 24.80 (-8.28%)
Pre-Market Technical Scan on Biotech Equities -- Cara Therapeutics, Catabasis Pharma, Catalyst Biosciences, and Celgene

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on CARA, CATB, CBIO, and CELG which can be accessed for free by signing up to www.wallstequities.com/registration....

CARA : 11.60 (-0.85%)
CELG : 76.61 (+2.57%)
CATB : 1.59 (-2.45%)
CBIO : 24.80 (-8.28%)
Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B

Initiation of Phase 2b Trial on Track for Q3 2018

CBIO : 24.80 (-8.28%)
Analysis: Positioning to Benefit within Catalyst Biosciences, CorEnergy Infrastructure Trust, PennyMac Mortgage Investment Trust, Raven Industries, Acacia Communications, and Sandy Spring -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Catalyst Biosciences, Inc....

RAVN : 39.05 (-1.76%)
CORR : 36.14 (-0.63%)
ACIA : 33.49 (+0.84%)
PMT : 18.67 (-0.16%)
CBIO : 24.80 (-8.28%)
SASR : 42.02 (+0.21%)
Catalyst Biosciences Receives $1.5 Million In Two Milestone Payments for Neuronal Nicotinic Receptor (NNR) Asset

The TC-6499 asset sale may provide up to $35.5 million in remaining development, regulatory and commercial milestone payments plus net sales royalties and sub-license fees

CBIO : 24.80 (-8.28%)
Catalyst Biosciences to Present at The Needham and Company 17th Annual Healthcare Conference

Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Nassim Usman, Ph.D., president...

CBIO : 24.80 (-8.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade CBIO with:

Business Summary

Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic...

See More

Key Turning Points

2nd Resistance Point 28.07
1st Resistance Point 26.43
Last Price 24.80
1st Support Level 23.73
2nd Support Level 22.66

See More

52-Week High 37.00
Last Price 24.80
Fibonacci 61.8% 24.05
Fibonacci 50% 20.06
Fibonacci 38.2% 16.06
52-Week Low 3.11

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar